AMA Backs Diversity in Clinical Trials
New policy designed to include more “women, sexual and gender minorities”
By Bruce Japsen
The American Medical Association’s House of Delegates adopted policy to ensure more women and sexual and gender minority populations are included in clinical trials and medical research.
Delegates meeting in June for their annual meeting in Chicago called on the AMA to support the U.S. Food and Drug Administration in requiring drug and device sponsors to develop “actionable clinical trial diversity action plans that include women, and sexual and gender minority populations.”
The idea, the AMA said, is to further the association’s efforts to ensure diversity in clinical research to improve health outcomes, particularly given the long history of medical devices and prescription medications “being developed without sufficient data on how they impact women, and sexual and gender minority populations,” the AMA said in a statement announcing the adoption of the new policy.
“For too long, women and sexual and gender minority (SGM) populations largely have been excluded from clinical trials and medical research—leading to unnecessary health inequities and negatively impacting the care these populations receive,” said AMA Board Member Toluwalase Ajayi, MD.
Document Actions